Editas Medicine (NASDAQ: EDIT)
Editas Medicine Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Editas Medicine Company Info
Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.
News & Analysis
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The company now has a chance to get its lead program out the door a bit sooner.
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The biotech has bounced back some in the past year.
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
2 Under-the-Radar Stocks With Incredible Upside Potential
It's also important to consider their downsides.
Could Editas Medicine Become the Next CRISPR Therapeutics?
The similarities between the pair are striking, but it might not be enough.
Down 88%, Could Editas Medicine Be a Good Investment Now?
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
These two are at very different stages of the clinical trials process.
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
Editas isn't out of the woods yet, but it's better off than before.
Valuation
Podcast Episodes
Earnings Transcripts
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
EDIT earnings call for the period ending September 30, 2021.
Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript
EDIT earnings call for the period ending June 30, 2021.
Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript
EDIT earnings call for the period ending March 31, 2021.
Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript
EDIT earnings call for the period ending .
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.